We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.10 | 9.00 | 9.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/3/2017 10:29 | First ever blood tests to diagnose cancer 'could be ready in one year'hTTp://www.inde | timojelly | |
24/3/2017 10:28 | Our next step... First ever blood tests to diagnose cancer 'could be ready in one year'http://www.inde | timojelly | |
17/3/2017 19:49 | Nice award nom for prem | hjb1 | |
17/3/2017 14:09 | lol some people sell on the back of that research note. Short minded people. It's in a up trend now so hold tight for the ride up and of course down sometimes as well. | thinkbig? | |
17/3/2017 14:02 | ... Mind you, it was quite a good run from third week in Feb! | small crow | |
17/3/2017 14:01 | Answer: some folk have interpreted today's RNS a little pessimistically. | small crow | |
17/3/2017 13:36 | why are we seeing a &% drop in the sp? | 2vdm | |
17/3/2017 12:11 | The trade that never was : "Sizeable Late trade : 2017-03-14 17:09:06 11.75 3,189,000 ? 374,708 O" | gooosed | |
17/3/2017 08:31 | . Litigation provision – This will have a significant influence on cashflows in the next two years, or even longer if the patent case were to go to appeal Prudent perhaps but not inspiring confidence. | gooosed | |
15/3/2017 08:18 | Looking at today's action I think you have the answer to last night's late trade! | mhw28865 | |
14/3/2017 18:40 | yes, a buy at that price imo. | hjb1 | |
14/3/2017 17:41 | Sizeable Late trade : 2017-03-14 17:09:06 11.75 3,189,000 ? 374,708 O | gooosed | |
14/3/2017 12:04 | Indeed: url for the announcement: | gnnmartin | |
14/3/2017 07:27 | Announcement by Horizon (HZD) surely relevant to us today, but I'm not sure exactly how! | small crow | |
08/3/2017 08:55 | I hope Prem people are on the phone this morning chasing payment, it's probably a legal thing anyway..I can't see they can carry on without either paying off all their debts or at least coming to some agreement to pay. | hjb1 | |
08/3/2017 08:14 | mhw28865, imv you summed it up.................. "I would hope so but you never know these days!" | twix386 | |
08/3/2017 07:50 | I would hope so but you never know these days! | mhw28865 | |
08/3/2017 07:44 | well their first job is to pay their debts before they do anything else. | hjb1 | |
08/3/2017 07:29 | I wonder what the chances are they will pay us what the owe when this is sorted. What do you think twix ? | mhw28865 | |
08/3/2017 07:03 | Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies Total investment can reach EUR 13 million upon exercise of share subscription warrants Transaction highlights Private placement of EUR 1 million launched today through the issuance of convertible notes with share subscription warrants attached Maximum additional potential financing of up to EUR 8 million through similar further private placements of convertible notes with share subscription warrants attached over the next 36 months, subject to fulfilment of certain conditions Upon the exercise of all share subscription warrants, the total investment can reach EUR 13 million Subscription by European Select Growth Opportunities Fund, a fund managed by L1 Capital Pty Ltd. Esperite to convene an extraordinary general meeting to present the details of the financing to its shareholders and to propose to approve the issuance of further tranches of convertible notes with share subscription warrants attached Proceeds to be used to support Esperite's commercial activities and development of innovative technologies in the field of genetics for Genoma and regenerative medicine for Cryo-Save and Cell Factory. | twix386 | |
07/3/2017 14:32 | I give them a better chance of success since they started looking for clients outside of the markets that are contested by the patent issue/litigation. | fse | |
07/3/2017 08:47 | Given that they have a war chest to fight the litigation with Illumina, I wonder whether the latter will back off or strike a deal. Either could be good for NIPT's future. | 2vdm | |
06/3/2017 18:20 | Interestingly these are back at the same price they started life at some 3 years ago. Given the litigation issue I suppose you could see this as some what going in the right direction again. Also I gather the NHS is still on board which cant be bad. | fse |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions